

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2696)

**PROPOSED CHANGE OF REGISTERED ADDRESS IN CHINA
AND
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

This announcement was made by Shanghai Henlius Biotech, Inc. (the “**Company**”) pursuant to Rule 13.51 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**the Listing Rules**”).

Proposed Change of Registered Address in China

The board of directors (the “**Board**”) of the Company announced that, based on the actual operations of the Company, the registered address of the Company will be changed from **Room 330, Complex Building, No. 222 Kangnan Road, China (Shanghai) Pilot Free Trade Zone** to **Room 901, 9th Floor, Building 1, No. 367 Shengrong Road, China (Shanghai) Pilot Free Trade Zone**, which will take effect from the date on which the proposed amendments to the existing articles of association of the Company (the “**Articles of Association**”) as described below are approved by the shareholders of the Company. The proposed change of registered address will not affect the head office and principal place of business of the Company in China.

Proposed Amendments to the Articles of Association

Due to the proposed change of the registered address of the Company, the update of applicable laws and regulations and regulatory requirements, and to further improve the corporate governance of the Company, the Board resolved to approve the amendments (the “**Proposed Amendments**”) to the Articles of Association at the Board meeting held on 21 March 2024, to, among other things, (1) reflect the change in the registered address of the Company; and (2) bring the Articles of Association in compliance with the latest law and regulatory requirements based on the real situations of the Company.

The proposed change to the registered address of the Company and the Proposed Amendments to the Articles of Associations are required to be filed and registered with the relevant authorities in the PRC. The Company will make adjustment to the wordings of such amendments and changes according to the comments of the relevant authorities (if any).

A circular containing, among other things, the details of the Proposed Amendments and the notice of the general meeting will be published by the Company in due course, and the Proposed Amendments will take effect upon the approval by shareholders at the general meeting by a special resolution. In addition, on the same day, the Board also resolved to approve and submitted to the general meeting for approval the proposed amendments to the rules of procedures for the general meetings, the rules of procedures for the board of directors and the rules of procedure for the board of supervisors of the Company. Details of the amendments will also be contained in the aforementioned circular.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 21 March 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.